Rozlytrek from Roche gets EC approval to treat solid tumours and NSCLC
The approval is based on results from the integrated analysis of the pivotal phase II STARTRK-2, phase I STARTRK-1 and phase I…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Rozlytrek
Roche’s personalised cancer treatment wins FDA approval
The treatment, Rozlytrek, is a tyrosine kinase inhibitor that targets patients who must be identified via genetic profiling